BMS265246 inhibits the activity of CDK4/cycD with IC50 of 0.23 ¦ÌM and prevents A2780 Cytox with IC50 of 0.76 ¦ÌM. BMS265246 which binds to CDK2 shows the inhibitor resides coincident with the ATP purine binding site and forms important H-bonds with Leu83 on the protein backbone. BMS265246 exhibits CDK1 and CDK2 potency that is 25- and 11-fold more potent versus CDK1 and CDK2, respectively. BMS265246 represents the most potent CDK/CDK2 selective analogue from this chemotype. A recent study shows that BMS-265246 inhibits cell proliferation with EC50 ranging from 0.293 ¦ÌM-0.492 ¦ÌM in HCT-116 cells. After treatment of BMS-265246, the dominant cell populations are G2-arrested cells having 4N DNA content, large round nuclei, and low DNA intensity.

June 21, 2017

prudect name : BMS265246 inhibits the activity of CDK4/cycD with IC50 of 0.23 ¦ÌM and prevents A2780 Cytox with IC50 of 0.76 ¦ÌM. BMS265246 which binds to CDK2 shows the inhibitor resides coincident with the ATP purine binding site and forms important H-bonds with Leu83 on the protein backbone. BMS265246 exhibits CDK1 and CDK2 potency that is 25- and 11-fold more potent versus CDK1 and CDK2, respectively. BMS265246 represents the most potent CDK/CDK2 selective analogue from this chemotype. A recent study shows that BMS-265246 inhibits cell proliferation with EC50 ranging from 0.293 ¦ÌM-0.492 ¦ÌM in HCT-116 cells. After treatment of BMS-265246, the dominant cell populations are G2-arrested cells having 4N DNA content, large round nuclei, and low DNA intensity.
BMS-265246

Synonyms: CAS NO: 582315-72-8Molecular Formula: C₁₈H₁₇F₂N₃O₂Molecular Weight: 345.34Purity: 98% minSolubility: In DMSOStorage: -20°C

1012054-59-9 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18503552